Nanobiotechnology in the Management of Glaucoma - Open Journal of Ophthalmology

OJOph > Vol.3 No.4, November 2013

Nanobiotechnology in the Management of Glaucoma ()

HTML

Download as PDF (Size: 139KB) PP. 127-133

DOI: 10.4236/ojoph.2013.34027 4,012 Downloads 6,986 Views Citations

Author(s)

Pho Nguyen, Alex Huang, Samuel C. Yiu

Affiliation(s)

Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
The Wilmer Eye Institute, Baltimore, USA; King Khaled Eye Specialist Hospital, Riyadh, KSA..

ABSTRACT

As the prevalence of glaucoma continues to rise, clinicians and researchers are confronted with an age-old problem: how to reduce risk factors and preserve vision in glaucoma. Current management options revolve around a validated paradigm—intraocular pressure reduction. Active investigations to improve drug delivery efficacy and surgical outcomes are flourishing. This article aims to provide the interested readers with a review of recent discoveries in nanobiotechnology for the management of glaucoma. Targeted drug-delivery systems using mesoscale vectors demonstrate promising delivery profiles. The utility of nanoparticulate therapies to support retinal ganglion cell survival is being investigated. Studies to modulate tissue regeneration and remodeling and improve post-trabeculectomy outcomes are underway. Though these modalities promise new avenues to manage glaucoma, immediate market availability is not anticipated soon.

KEYWORDS

Glaucoma; Nanotechnology; Nanomedicine; Drug Delivery; Wound Healing; Nanoparticle

Share and Cite:

Nguyen, P. , Huang, A. and Yiu, S. (2013) Nanobiotechnology in the Management of Glaucoma. Open Journal of Ophthalmology, 3, 127-133. doi: 10.4236/ojoph.2013.34027.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies